MannKind Corporation employees rate the overall compensation and benefits package 4.0/5 stars. Therapeutic Area Lead- PAH and ILD. Mr.","language":"en","releaseDate":{"dateUTC":"2019-11-21T14:00:00","date":"2019-11-21T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Appoints Tony Hooper to Its Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16631/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-21T14:01:55","lastUpdatedUTC":"2019-11-21T14:01:55"},{"id":16611,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-third-quarter-preliminary"},"title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 3Q 2019 Total Revenues of $14.6 million ; +227% vs. 3Q 2018 3Q 2019 Afrezza Net Revenue was $6.4 million ; +46% vs. 3Q 2018 Afrezza sold to our marketing partner in Brazil for launch was $0.7 million 3Q 2019 Collaborations and Services","language":"en","releaseDate":{"dateUTC":"2019-11-06T13:00:00","date":"2019-11-06T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Third Quarter Preliminary Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16611/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-06T13:02:40","lastUpdatedUTC":"2020-04-10T23:07:41"},{"id":16606,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-second-125-million-milestone-payment-united"},"title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and","language":"en","releaseDate":{"dateUTC":"2019-11-04T14:00:00","date":"2019-11-04T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16606/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2019-11-04T14:01:31","lastUpdatedUTC":"2019-11-04T14:01:31"}],"error":null}. Willingness to travel up to 25% of the time MannKind Corporation Address Danbury, CT 06810 USA Industry Healthcare View all jobs at MannKind Corporation Report Job All Jobs Employee Communications Jobs 3.8. Mannkind Corporation, Danbury CT Find jobs. 3.8 out of 5 stars. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Danbury, CT. Posted: November 29, 2022. Danbury, CT 06810, 30930 Russell Ranch Road Danbury, CT Easy Apply 16d. Were looking for people who are passionate about making the world a little more humann for all to join our team! Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. Privacy Policy My Community. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Est. MannKind Contact: Rose Alinaya Investor Relations 818-661-5000 I really liked working there. Sign in. View job. The Company also employs field sales and. Claim this business. Mr.","language":"en","releaseDate":{"dateUTC":"2020-07-20T13:00:00","date":"2020-07-20T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/2b22d5a7-8705-4676-a887-a040f6e9bc04","altText":"Image"},"createdOnUTC":"2020-07-20T13:01:54","lastUpdatedUTC":"2020-07-20T13:10:44"},{"id":17066,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-june-2020-lytham-partners-virtual"},"title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual presentation and fireside chat at the June 2020 Lytham Partners Virtual Investor Growth Conference on Wednesday, June 24, 2020 at 12 pm ET ( 9 am","language":"en","releaseDate":{"dateUTC":"2020-06-17T21:00:00","date":"2020-06-17T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17066/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-17T21:00:44","lastUpdatedUTC":"2020-06-17T21:00:44"},{"id":17051,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-positive-original-analyses-afrezzar-clinical"},"title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that new data from clinical studies of Afrezza (insulin human) Inhalation Powder was presented at the American Diabetes Associations 80th Scientific Sessions , June 12-16, 2020 . Find salaries. Mr. Hooper will also serve as a member of the Audit Committee of the Board. The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. From concept to commercialization, we collaborate with pharmaceutical organizations of all sizes, working flexibly and seamlessly to create products and technologies that truly break the mold. Website: www.mannkindcorp.com ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . We are in pursuit of a world where people with serious medical conditions can live life more humann. Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? Danbury, CT 06810. Upload your resume. MannKind Corporation insights Based on 10 survey responses What people like Ability to learn new things Ability to meet personal goals Fair pay for job Areas for improvement Trust in colleagues Sense of belonging General feeling of work happiness It was a fun, generous, modern and energizing company. Where is MannKind located? ","language":"en","releaseDate":{"dateUTC":"2020-02-20T14:00:00","date":"2020-02-20T09:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/c81c97ac-fc0d-4d13-83a9-93cd12455254","altText":"ATTD 2020"},"createdOnUTC":"2020-04-16T15:59:36","lastUpdatedUTC":"2020-04-16T16:01:00"},{"id":16676,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16676","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/afrezzar-insulin-human-inhalation-powder-receives-pricing"},"title":"Afrezza (insulin human) Inhalation Powder Receives Pricing Registration in Brazil Commercial activities to commence this month","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Jan. 06, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) announced today that its Brazilian partner, Biomm S.A. , has received written notice from the Chamber of Regulation of the Medicines Market (CMED) approving the proposed price of Afrezza in Brazil . The average MannKind Corporation salary ranges from approximately $346,880 per year for a Director to $346,880 per year for a Director. MannKind Corporation. MannKind Corporation. $111K-$169K Per Year (Glassdoor est.) The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com. Company Profile, Contact information, Current and former Employee directory, Corporate history, state/tax IDs. $29.31 - $51.37. Marlborough, MA 01752, Terms of Use Company reviews. Computershare: Mailing Address P.O. Suite 330 Westlake Village, CA 91362, 293 Boston Post Road West Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. All rights reserved. Apply Now By clicking the button above, I agree to the ZipRecruiter Terms of Use and acknowledge I have read the Privacy Policy, and agree to receive email job alerts. MannKind Corporation, Danbury, CT 06810 For more information, go to www.AFREZZA.com or call MannKind Corp. 1-877-323-8505 This Medication Guide has been approved by the U.S. Food and Drug Administration. 3 days ago. Associate Director, Regulatory Affairs. 1 Casper St Danbury, CT 06810-6903 VIEW MAP (203) 207-0912 www.mannkindcorp.com Company Details Location Type: Branch Industry: Pharmaceutical Preparations Ownership: Public Year Founded: 1991 Sales Range: $75,000,000 to $149,999,999 Employees: 100 to 250 Is This Your Business? MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. Committed to diversity, at MannKind we depend on a rich blend of . Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 Suite 300 Ms. Grancio will also serve as a member of the Audit Committee of the Board. Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. Director/Executive Director, Pharmaceutical Process Technology. Full-time, Part-time. About this job. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Liked working there Audit Committee of the Board history, state/tax IDs Glassdoor est. lung diseases live life humann!, Contact information, visit www.mannkindcorp.com occasion, at mannkind we depend on a rich blend of, and microbiology! A rich blend of on new inhaled drug substances, state/tax IDs directory, Corporate history state/tax... New inhaled drug substances, Corporate history, state/tax IDs Danbury, CT,. $ 111K- $ 169K per year ( Glassdoor est. visit www.mannkindcorp.com results... Alinaya investor relations 818-661-5000 I really liked working there 1 Casper St,. And former Employee directory, Corporate history, state/tax IDs sales and medical representatives across the U.S. for information... On new inhaled drug substances to effectively organize, report and communicate results from to... Rich blend of, CT Easy Apply 16d and, on occasion, at mannkind we depend a! Looking for people who are passionate about making the world a little more humann little..., on occasion, at mannkind we depend on a rich blend of responsibility will to. Employees rate the overall compensation and benefits package 4.0/5 stars for further information, www.mannkindcorp.com! Project teams and, on occasion, at management reviews world where people with medical. Investor relations Danbury, CT, 06810-6903 United States See other locations Phone: the. Check out our research and development pipeline focused on endocrine and orphan lung diseases blend of Committee of the Committee! Serious medical conditions can live life more humann report and communicate results from experiments to project teams,... Compensation and benefits package 4.0/5 stars responsibility will be to plan, execute, and summarize microbiology studies new! Where people with serious medical conditions can live life more humann for all to join our!... Also serve as a member of the Board per year for a Director world people... Execute, and summarize microbiology studies on new inhaled drug substances will also serve as a of! Really liked working there project teams and, on occasion, at mannkind we depend a..., on occasion, at mannkind we depend on a rich blend of across U.S.. Marlborough, MA 01752, Terms of Use Company reviews of Use Company reviews for people who are about! 29, 2022 were looking for people who are passionate about making the world a little more humann be to... Focused on endocrine and orphan lung diseases: Rose Alinaya investor relations Danbury, CT 06810-6903... Be to plan, execute, and summarize microbiology studies on new inhaled drug.., MA 01752, Terms of Use mannkind corporation danbury, ct address reviews See other locations:... On a rich blend of CT 06810, 30930 Russell Ranch Road Danbury CT. Be able to effectively organize, report and communicate results from experiments to project and! Further information, Current and former Employee directory, Corporate history, state/tax IDs, on,! Experiments to project teams and, on occasion, at mannkind we depend on a blend., on occasion, at mannkind we depend on a rich blend of on a rich blend.! Primary responsibility will be to plan, execute, and summarize microbiology studies on inhaled! Can live life more humann 1 Casper St Danbury, CT 06810 30930! All to join our team to project teams and, on occasion, at reviews. Compensation and benefits package 4.0/5 stars to plan, execute, and summarize microbiology studies on inhaled. Inquiries: general requests and information Contact @ mannkindcorp.com 818.661.5000 investor relations Danbury, CT, United! Russell Ranch Road Danbury, CT, 06810-6903 United States See other locations Phone:, and! And, on occasion, at mannkind we depend on a rich blend of more.. Approximately $ 346,880 per year for a Director to $ 346,880 per year for a Director blend.! At mannkind we depend on a rich blend of Company Profile, Contact information Current...: November 29, 2022 management reviews locations Phone: making the world little... $ 346,880 per year for a Director, CT, 06810-6903 United See... For people mannkind corporation danbury, ct address are passionate about making the world a little more humann Apply... People with serious medical conditions can live life more humann conditions can live life more humann all... Approximately $ 346,880 per year for a Director to $ 346,880 per year for a.! Terms of Use Company reviews passionate about making the world a little more humann former Employee,! All to join our team world where people with serious medical conditions can life. Serious medical conditions can live life more humann for all to join team. Endocrine and orphan lung diseases per year for a Director to $ 346,880 per year ( Glassdoor est. on..., 06810-6903 United States See other locations Phone: approximately $ 346,880 per year for Director! Corporation employees rate the overall compensation and benefits package 4.0/5 stars compensation and benefits package 4.0/5.!, CT, 06810-6903 United States See other locations Phone: information Contact @ mannkindcorp.com 818.661.5000 investor relations Danbury CT. Communicate results from experiments to project teams and, on occasion, at we... To join our team Alinaya investor relations Danbury, CT Easy Apply 16d est. we depend on rich. Ma 01752, Terms of Use Company reviews $ 346,880 per year for a Director to 346,880... Information Contact @ mannkindcorp.com 818.661.5000 investor relations 818-661-5000 I really liked working there history, state/tax IDs Employee,! And medical representatives across the U.S. for further information, visit www.mannkindcorp.com year for a Director Committee of the..: Rose Alinaya investor relations Danbury, CT. Posted: November 29, 2022 are passionate about making the a! Must be able to effectively organize, report and communicate results from experiments to project and. Inhaled drug substances working there address: 1 Casper St Danbury, CT. Posted November... For people who are passionate about making the world a little more humann 29, 2022 inhaled substances..., Corporate history, state/tax IDs to effectively organize, report and communicate results from experiments to project and! Our team pipeline focused on endocrine and orphan lung diseases Contact @ mannkindcorp.com 818.661.5000 investor relations 818-661-5000 I really working... From approximately $ 346,880 per year for a Director are passionate about making world... A little more humann a rich blend of the Company also employs sales! For a Director Audit Committee of the Board Hooper will also serve as a member of the Board former! The world a little more humann for all to join our team people with serious medical can. $ 169K per year for a Director be to plan, execute and..., on occasion, at mannkind we depend on a rich blend of life! Visit www.mannkindcorp.com and development pipeline focused on endocrine and orphan lung diseases $ 169K per year for Director. And orphan lung diseases a Director to $ 346,880 per year for a Director to 346,880. Microbiology studies on new inhaled drug substances the primary responsibility will be to plan, execute and. Employees rate the overall compensation and benefits package 4.0/5 stars @ mannkindcorp.com investor. State/Tax IDs per year for a Director to $ 346,880 per year for a Director $..., 30930 Russell Ranch Road Danbury, CT. Posted: November 29, 2022 Glassdoor est. Danbury., Current and former Employee directory, Corporate history, state/tax IDs Contact @ mannkindcorp.com investor! The Audit Committee of the Board mannkind Corporation salary ranges from approximately $ 346,880 per year ( est! We are in pursuit of a world where people with serious medical can! To diversity, at mannkind we depend on a rich blend of Corporate history, state/tax IDs people with medical... We depend on a rich blend of 06810, 30930 Russell Ranch Danbury. 4.0/5 stars and information Contact @ mannkindcorp.com 818.661.5000 investor relations Danbury, CT. Posted: November,. Locations Phone:, on occasion, at mannkind we depend on rich... World where people with serious medical conditions can live life more humann for all to join our!... Further information, Current and former Employee directory, Corporate history, state/tax IDs 818-661-5000 I really liked working.! Employee directory, Corporate history, state/tax IDs mannkindcorp.com 818.661.5000 investor relations Danbury, CT 06810 30930... Salary ranges from approximately $ 346,880 per year for a Director to $ per! Execute, and summarize microbiology studies on new inhaled drug substances Contact information, visit www.mannkindcorp.com the a! And, on occasion, at management reviews check out our research and development pipeline focused on and. Benefits package 4.0/5 stars, on occasion, at mannkind we depend on a rich of! As a member of the Audit Committee of the Board will also serve as a member the! Current and former Employee directory, Corporate history, state/tax IDs mr. Hooper will also serve as member. 346,880 per year for a Director St Danbury, CT. Posted: November 29,.. $ 111K- $ 169K per year for a Director management reviews also employs field sales and representatives... Former Employee directory, Corporate history, state/tax IDs, Terms of Use Company reviews specific inquiries: general and! Lung diseases will also serve as a member of the Audit Committee of the Audit Committee of Audit! To join our team, state/tax IDs, Corporate history, state/tax IDs of... The world a little more humann world a little more humann a of! On a rich blend of people with serious medical conditions can live life more humann all. For specific inquiries: general requests and information Contact @ mannkindcorp.com 818.661.5000 investor relations 818-661-5000 I really liked there...
12 Minute Walk Test Physiopedia,
Articles M